JP3886116B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP3886116B2 JP3886116B2 JP2002140844A JP2002140844A JP3886116B2 JP 3886116 B2 JP3886116 B2 JP 3886116B2 JP 2002140844 A JP2002140844 A JP 2002140844A JP 2002140844 A JP2002140844 A JP 2002140844A JP 3886116 B2 JP3886116 B2 JP 3886116B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- willow
- salicaceae
- skin
- salix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 26
- 230000000699 topical effect Effects 0.000 title description 5
- 239000000284 extract Substances 0.000 claims description 78
- 241000218998 Salicaceae Species 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000419 plant extract Substances 0.000 claims description 18
- 241001278079 Salix nigra Species 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 13
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 10
- 229940069445 licorice extract Drugs 0.000 claims description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 4
- 241000736199 Paeonia Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 4
- 229950002760 sodium gualenate Drugs 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 2
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims 1
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- VIZXMHCBZLGUET-UHFFFAOYSA-N sodium gualenate Chemical compound CC(C)C1=CC=C(C)C2=C(S(O)(=O)=O)C=C(C)C2=C1 VIZXMHCBZLGUET-UHFFFAOYSA-N 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 241000124033 Salix Species 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 24
- 239000012071 phase Substances 0.000 description 22
- 239000008213 purified water Substances 0.000 description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 229940121363 anti-inflammatory agent Drugs 0.000 description 18
- 239000002260 anti-inflammatory agent Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 16
- -1 water Chemical compound 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 241001278097 Salix alba Species 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 241001481760 Erethizon dorsatum Species 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 229940058015 1,3-butylene glycol Drugs 0.000 description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 description 8
- 229960000541 cetyl alcohol Drugs 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 244000020191 Salix babylonica Species 0.000 description 7
- 235000002493 Salix babylonica Nutrition 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 7
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 7
- 230000037373 wrinkle formation Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229940075507 glyceryl monostearate Drugs 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001299682 Salix purpurea Species 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
- 241000555712 Forsythia Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 241000756137 Hemerocallis Species 0.000 description 3
- 241000219000 Populus Species 0.000 description 3
- 241000183024 Populus tremula Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 241000218978 Populus deltoides Species 0.000 description 2
- 241001277509 Salix arbutifolia Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008269 hand cream Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000008820 moutan cortex Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000010330 ougon Substances 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NZGKLLOWEPXNDG-SSCMEWPNSA-N (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-octadecanoyloxy-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1(C)C NZGKLLOWEPXNDG-SSCMEWPNSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- AVBJHQDHVYGQLS-UHFFFAOYSA-N 2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)NC(C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WLMZUANPXHJWCH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dodecanoic acid Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCC(O)=O WLMZUANPXHJWCH-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QRTADFOPPOKFDH-UHFFFAOYSA-N 20,21-dihydroxyhenicosanoic acid Chemical compound OCC(O)CCCCCCCCCCCCCCCCCCC(O)=O QRTADFOPPOKFDH-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical class C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- OTTPFCJTQXRWHO-UHFFFAOYSA-N 3-(2,3-dichloroanilino)cyclohex-2-en-1-one Chemical compound ClC1=CC=CC(NC=2CCCC(=O)C=2)=C1Cl OTTPFCJTQXRWHO-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- XFFQVRFGLSBFON-UHFFFAOYSA-N 5alpha,12-dihydroxy-6(14)-dehydro-5,6-dihydrocaryophyllen-7-one Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(CO)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 XFFQVRFGLSBFON-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 241000934653 Dero Species 0.000 description 1
- 241000282327 Felis silvestris Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BVRYLTBIGIAADD-MRXNPFEDSA-N Isobutylshikonin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-MRXNPFEDSA-N 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000168036 Populus alba Species 0.000 description 1
- 241001278112 Populus euphratica Species 0.000 description 1
- 241000218982 Populus nigra Species 0.000 description 1
- 241000734097 Populus nigra var. italica Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241000390729 Salix acutifolia Species 0.000 description 1
- 241000646858 Salix arbusculoides Species 0.000 description 1
- 241001249584 Salix bakko Species 0.000 description 1
- 235000000516 Salix caprea Nutrition 0.000 description 1
- 241001278105 Salix chaenomeloides Species 0.000 description 1
- 241001277119 Salix gilgiana Species 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 235000005887 Salix gracilistyla Nutrition 0.000 description 1
- 241001278091 Salix integra Species 0.000 description 1
- 241000819176 Salix japonica Species 0.000 description 1
- 241001352116 Salix laevigata Species 0.000 description 1
- 241000779709 Salix matsudana Species 0.000 description 1
- 241000125000 Salix nakamurana Species 0.000 description 1
- 241001278083 Salix reinii Species 0.000 description 1
- 241001299685 Salix schwerinii Species 0.000 description 1
- 241001278113 Salix urbaniana Species 0.000 description 1
- 241000124015 Salix viminalis Species 0.000 description 1
- 240000002751 Sideroxylon obovatum Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IHUMNXSBUOIDQI-UHFFFAOYSA-N Triethanolamine myristate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCC(O)=O IHUMNXSBUOIDQI-UHFFFAOYSA-N 0.000 description 1
- UTOUNDHZJFIVPK-QGZVFWFLSA-N [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-methylbutanoate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](CC=C(C)C)OC(=O)CC(C)C)=CC(=O)C2=C1O UTOUNDHZJFIVPK-QGZVFWFLSA-N 0.000 description 1
- WNFXUXZJJKTDOZ-OAHLLOKOSA-N [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-OAHLLOKOSA-N 0.000 description 1
- AZPFEYANVWPOHJ-CLFAGFIQSA-N [2-hydroxy-3-[2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]propyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCCCCCC\C=C/CCCCCCCC AZPFEYANVWPOHJ-CLFAGFIQSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000001545 azulenes Chemical class 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- AEJIMXVJZFYIHN-UHFFFAOYSA-N copper;dihydrate Chemical compound O.O.[Cu] AEJIMXVJZFYIHN-UHFFFAOYSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RBHFPIHDGCGQPN-UHFFFAOYSA-N ethyl 3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound C1=C(C(C)C)C=CC(C)=C2C(S(=O)(=O)OCC)=CC(C)=C21 RBHFPIHDGCGQPN-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- KVMXBSSOCCPAOR-UHFFFAOYSA-N ginsenoside ra1 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C(C1O)O)OCC1OC1OCC(O)C(O)C1O KVMXBSSOCCPAOR-UHFFFAOYSA-N 0.000 description 1
- UEBIBJSWHIZNCA-UHFFFAOYSA-N ginsenoside ra2 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1OC1OCC(O)C(O)C1O UEBIBJSWHIZNCA-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- BVRYLTBIGIAADD-UHFFFAOYSA-N isobutyryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- UTOUNDHZJFIVPK-UHFFFAOYSA-N shikonin isovalerate Natural products C1=CC(O)=C2C(=O)C(C(CC=C(C)C)OC(=O)CC(C)C)=CC(=O)C2=C1O UTOUNDHZJFIVPK-UHFFFAOYSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、肌荒れ及び皮膚の老化の防止，改善効果が相乗的に向上した皮膚外用剤に関する。さらに詳しくはヤナギ科（S0alicaceae）植物抽出物と、抗炎症剤とを併用して成る皮膚外用剤に関する。
【０００２】
【従来の技術】
加齢や紫外線曝露，皮膚組織内において発生する活性酸素種等による酸化的ストレス、薬物や種々のアレルゲンとの接触などにより、皮膚の炎症反応や皮膚の老化が進行することが知られている。これまで皮膚外用剤の分野では、かかる皮膚の炎症や老化を防止するべく、活性酸素種消去剤や抗炎症剤，抗アレルギー剤等多くの生理活性成分の探索及び検討がなされてきた。また、加齢や前記ストレスにより、真皮マトリックス成分であるコラーゲンの架橋等修飾により皮膚の老化症状が進行することが明らかになるにつれ、皮膚組織内においてその産生を促進する作用を有する物質の検討もなされている。近年は、消費者の天然志向及び植物志向を反映してか、かかる成分を植物に求める傾向が強くなっている。
【０００３】
しかしながら、すでに報告されている植物起源の上記成分の中には、活性が低いため、皮膚外用剤に配合して十分な作用効果を得るにはかなりの高濃度を要したり、安定性や安全性上問題があったり、皮膚外用剤に好ましくない色や臭いを付与してしまうものがあったりして、皮膚外用剤に配合した際に、製剤安定性及び安全性と、作用効果のすべての面で満足できるものは少ないのが現状であった。また皮膚の炎症反応や老化は、種々の要因が複雑に関与し合って進行するため、前記反応の一部の過程のみに作用する物質を用いても十分な効果は得られなかった。
【０００４】
【発明が解決しようとする課題】
そこで本発明においては、複雑な皮膚の炎症性反応等を抑制し、肌荒れや皮膚の老化の防止，改善効果が相乗的に向上した皮膚外用剤を得ることを目的とした。
【０００５】
【課題を解決するための手段】
上記課題を解決するべく種々検討したところ、本発明者らはヤナギ科（Salicaceae）植物抽出物と、抗炎症剤の１種又は２種以上とを併用して皮膚外用剤に含有させることにより、肌荒れ及び皮膚の老化の防止，改善効果の相乗的な向上が得られることを見いだし、本発明を完成するに至った。
【０００６】
ヤナギ科（Salicaceae）植物抽出物の有効性については、葉に含まれるジヒドロミリセナンの美白作用（特開昭６３−３１６７１１）及び抗変異原作用（特開平１−１７５９３２）、樹皮抽出物のヒスタミン遊離抑制作用（特開平１０−２８７５８２）、樹皮や葉に多く含まれるサリシンの線維芽細胞賦活作用（特開平１１−８０００２）等が既に知られている。
【０００７】
また、抗炎症剤については、肌荒れ改善効果を期待して、古くから皮膚外用剤に配合されているが、ヤナギ科（Salicaceae）植物抽出物と、抗炎症剤とを併用することにより得られる本発明の効果は、これまで全く示唆すらされていない。
【０００８】
【発明の実施の形態】
本発明に用いるヤナギ科（Salicaceae）の植物としては、ケショウヤナギ属のケショウヤナギ(Chosenia arbutifolia (Pallas) A. Skvortz ; Chosenia bracteosa Nakai)、ハコヤナギ（ヤマナラシ，ポプラ）属のハコヤナギ（ヤマナラシ）(Populus sieboldi Miq.)，デロ（ドロノキ）(Populus maxmowiczii Henry)，ウラジロハコヤナギ（ギンドロ）(Populus alba L.)，アメリカクロヤマナラシ(Populus deltoides Marsh.;Populus monilifera Ait. ; Populus angulata Aiv.)，コトカケヤナギ(Populus euphratica Oliv.)，ヨーロッパクロヤマナラシ(Populus nigra L.)，セイヨウハコヤナギ(Populus nigra var. italica Koehne)，ヨーロッパヤマナラシ(Populus tremula)、ヤナギ属のカスピヤナギ(Salix acutifolia L.)，ヨーロッパヤナギ(Salix alba L.;Salix aurea Salisb.)，シダレヤナギ（イトヤナギ）(Salix babylonica L.)，ヤマネコヤナギ（バッコヤナギ）(Salix bakko Kimura)，アカメヤナギ(Salix chaenomeloides Kimura)，ナガバカワヤナギ(Salix gilgiana Seemen.)，ネコヤナギ（エノコロヤナギ，カワヤナギ）(Salix gracilistyla Miq.)，イヌコリヤナギ(Salix integra Thunb.)，シバヤナギ(Salix japonica Thunb.)，キヌヤナギ(Salix kinuyanagi Kimura)，コリヤナギ(Salix koriyanagi Kimura ; Salix purpurea var. japonica Nakai)，フリソデヤナギ(Salix leucopithecia Kimura)，ウンリュウヤナギ(Salix matsudana Koidz.)，タカネイワヤナギ（レンゲイワヤナギ）(Salix nakamurana Koidz.)，クロヤナギ(Salix nigra)，ムラサキヤナギ(Salix purpurea L.)，オノエヤナギ（カラフトヤナギ）(Salix sachalinensis Fr. Schm.)，ミヤマヤナギ（ミネヤナギ）(Salix reinii Fr. et Sav.)，ヤマヤナギ(Salix sieboldiana Bl.)，タイリクキヌヤナギ(Salix viminalis L. ; Salix longifolia Lam.) ，キツネヤナギ（イワヤナギ）(Salix vulpina)、オオバヤナギ属のオオバヤナギ(Toisusu urbaniana ; Salix urbaniana)等が例示される。これらの中でもその抗菌作用の点から特に、ヨーロッパヤマナラシ(Populus tremula)，ヨーロッパヤナギ(Salix alba L. ; Salix aurea Salisb.)，シダレヤナギ（イトヤナギ）(Sali x babylonica L.)，クロヤナギ(Salix nigra)，ムラサキヤナギ(Salix purpurea L.)から選択される１種又は２種以上の植物を用いることが好ましく、さらにはクロヤナギ(Salix nigra)樹皮抽出物が最も好ましい。ヤナギ科（Salicaceae）植物から抽出物を得る際の部位は、特に限定されないが、その抗菌作用の点から樹皮，葉及び雌花が好ましく用いられる。
【０００９】
これらのヤナギ科（Salicaceae）植物の抽出物を得る抽出溶媒としては、水、エタノール，メタノール，イソプロパノール，イソブタノール，n-ヘキサノール，メチルアミルアルコール，2-エチルブタノール，n-オクチルアルコールなどのアルコール類、グリセリン，エチレングリコール，エチレングリコールモノメチルエーテル，エチレングリコールモノエチルエーテル，プロピレングリコール，プロピレングリコールモノメチルエーテル，プロピレングリコールモノエチルエーテル，トリエチレングリコール，1,3-ブチレングリコール，ヘキシレングリコール等の多価アルコール又はその誘導体、アセトン，メチルエチルケトン，メチルイソブチルケトン，メチル-n-プロピルケトンなどのケトン類、酢酸エチル，酢酸イソプロピルなどのエステル類、エチルエーテル，イソプロピルエーテル，n-ブチルエーテル等のエーテル類などの極性溶媒から選択される１種又は２種以上の混合溶媒が好適に使用でき、また、リン酸緩衝生理食塩水をも用いることができるが、特に限定はされない。本発明の目的には、抗菌活性の点から、極性溶媒が好ましく、さらには、メタノール，エタノール，1,3-ブチレングリコール，水から選択される１種又は２種以上の混合溶媒、特に水を溶媒とすることが好ましい。
【００１０】
抽出方法としては、室温，冷却又は加温した状態で浸漬させて抽出する方法、水蒸気蒸留等の蒸留法を用いて抽出する方法、生のヤナギ科（Salicaceae）植物から圧搾して抽出物を得る圧搾法等が例示され、これらの方法を単独で、又は２種以上を組み合わせて抽出を行う。
【００１１】
抽出の際のヤナギ科（Salicaceae）植物と溶媒との比率は特に限定されるものではないが、ヤナギ科（Salicaceae）植物１に対して溶媒０．５〜１０００重量倍、特に抽出操作、効率の点で０．５〜１００重量倍が好ましい。また、抽出温度は、常圧下で室温から溶剤の沸点以下の範囲とするのが便利であり、抽出時間は抽出温度などによって異なるが、２時間〜２週間の範囲とするのが好ましい。
【００１２】
また、このようにして得られたヤナギ科（Salicaceae）植物抽出物は、抽出物をそのまま用いることもできるが、本発明の抗菌作用を失わない範囲内で脱臭，脱色，濃縮等の精製操作を加えたり、さらにはカラムクロマトグラフィー等を用いて分画物として用いてもよい。これらの抽出物や精製物、分画物は、これらから溶媒を除去することによって乾固物とすることもでき、さらにアルコールなどの溶媒に可溶化した形態、或いは乳剤の形態で提供することができる。
【００１３】
本発明において、上記ヤナギ科（Salicaceae）植物抽出物と併用する抗炎症剤としては、コルチゾン，ヒドロコルチゾン，プレドニゾロン，メチルプレドニゾロン，デキサメタゾン，ベタメタゾン，トリアムシノロン，トリアムシノロンアセトニド，フルオシノロンアセトニド，フルオシノニド，ベクロメタゾン及びこれらのリン酸塩，プロピオン酸塩，酢酸塩，コハク酸塩等のステロイド性抗炎症剤、サリチル酸及びアスピリン，サリチルアミド，エテンザミド，サリチル酸メチル等のサリチル酸誘導体、インドメタシン，スリンダク等のインドール酢酸誘導体、フェニルブタゾン，オキシフェンブタゾン等のピラゾリジンジオン誘導体、メフェナム酸，フルフェナム酸等のアントラニル酸誘導体、イブプロフェン，ケトプロフェン，ナプロキセン等のプロピオン酸誘導体、ジクロフェナック，フェンブフェン，ブフェキサマク等のフェニル酢酸誘導体、ピロキシカム等のベンゾチアジン誘導体といった非ステロイド性抗炎症剤、グリチルリチン酸及びグリチルリチン酸ジカリウム，グリチルリチン酸モノアンモニウム等のグリチルリチン酸の塩並びに誘導体、グリチルレチン酸及びグリチルレチン酸ステアリル，ステアリン酸グリチルレチニル，3-サクシニルオキシグリチルレチン酸二ナトリウム等のグリチルレチン酸の塩並びに誘導体、グアイアズレン，グアイアズレンスルホン酸エチル，グアイアズレンスルホン酸ナトリウム，カマズレン等のアズレン誘導体、アラントイン、アロイン、アロエエモジン、シコニン及びイソブチルシコニン，アセチルシコニン，イソバレリルシコニン等のシコニン誘導体、ギンセノシドＲa1，ギンセノシドＲa2，ギンセノシドＲb1等のギンセノシド、及び20-グルコギンセノシドＲf等のギンセノシド誘導体、ペオニフロリン、ペオノール及びペオノシド，ペオノリド等のペオノール誘導体などが挙げられる。
【００１４】
また本発明においては抗炎症剤として、オウゴン（Scutellariae Radix），カンゾウ（Glycyrrhizae Radix），クジン（Sophorae Radix），サイコ（Bupleuri Radix），シャクヤク（Paeoniae Radix），ショウマ（Cimicifugae Rhizoma），タイソウ（Zizyphi Fructus），チモ（Anemarrhenae Rhizoma），ボタンピ（Moutan Cortex），リュウタン（Gentianae Scabrae Radix），レンギョウ（Forsythiae Fructus）等、抗炎症剤として用いられる生薬又はその抽出物を用いることもできる。
【００１５】
本発明に係る皮膚外用剤には、これら抗炎症剤より１種又は２種以上を選択して用いる。
【００１６】
本発明における抗炎症剤としては、皮膚外用剤への配合のしやすさから、グリチルリチン酸の塩並びに誘導体、グリチルレチン酸の塩並びに誘導体、カンゾウから選択される１種又は２種以上が好ましく用いられ、肌荒れ改善効果の点から、グリチルレチン酸ステアリル及びカンゾウ抽出物から選択される１種又は２種を用いることが好ましい。
【００１７】
本発明においては、ヤナギ科（Salicaceae）植物抽出物と、抗炎症剤の１種又は２種以上とを皮膚外用剤基剤に含有させる。皮膚外用剤全量あたりの配合量としては、ヤナギ科（Salicaceae）植物抽出物については０．００１〜５．０重量％程度、とするのが適切である。抗炎症剤についてはその種類により異なるが、０．０００１〜５．０重量％程度とするのが適切である。
【００１８】
本発明に係る皮膚外用剤は、ローション剤，乳剤，ゲル剤，クリーム剤，軟膏剤，粉末剤，顆粒剤等、種々の剤型で提供することができる。また、化粧水，乳液，クリーム，美容液，パック等の皮膚化粧料、メイクアップベースローション，メイクアップベースクリーム等の下地化粧料、乳液状，油性，固形状等の各剤型のファンデーション，アイカラー，チークカラー等のメイクアップ化粧料、ハンドクリーム，レッグクリーム，ネッククリーム，ボディローション等の身体用化粧料等として提供することができる。
【００１９】
なお本発明に係る皮膚外用剤には、ヤナギ科（Salicaceae）植物抽出物及び抗炎症剤の他に、油性成分，界面活性剤，保湿剤，顔料，紫外線吸収剤，抗酸化剤，香料，防菌防黴剤等の一般的な医薬品及び化粧料用原料や、皮膚細胞賦活剤，美白剤等の生理活性成分を含有させることができる。
【００２０】
【実施例】
さらに本発明の特徴について、実施例により詳細に説明する。
【００２１】
まず、本発明に係る皮膚外用剤に含有させるヤナギ科（Salicaceae）植物抽出物の調製について示す。
【００２２】
［クロヤナギ樹皮抽出物］
春に採取したクロヤナギ（Salix nigra）の新鮮な樹皮２００ｇを細片化したものに、精製水１０００ｇを加え、２５℃で撹拌しながら３６時間抽出する。得られたエキスをろ過した後、減圧濃縮して、１５０ｇのクロヤナギ樹皮抽出物を得た。
【００２３】
［ヨーロッパヤマナラシ葉抽出物］
ヨーロッパヤマナラシ(Populus tremula)の新鮮な葉２００ｇを細片化したものに、精製水１０００ｇを加え、２５℃で撹拌しながら３６時間抽出する。得られたエキスをろ過した後、減圧濃縮して、１２０ｇのヨーロッパヤマナラシ葉抽出物を得た。
【００２４】
［ヨーロッパヤナギ樹皮抽出物］
乾燥したヨーロッパヤナギ(Salix alba L. ; Salix aurea Salisb.)５０ｇを粉砕し、５０容量％エタノール１０００ｇを加え、室温で２４時間抽出する。得られたエキスをろ過した後、減圧濃縮後、凍結乾燥して５ｇのヨーロッパヤナギ樹皮抽出物を得た。
【００２５】
［シダレヤナギ葉抽出物］
新鮮なシダレヤナギ（イトヤナギ）(Salix babylonica L.)新芽１０ｇに精製水１００ｇを添加して、ミキサーで１０分間撹拌抽出を行う。得られたエキスをろ過した後、減圧濃縮後、凍結乾燥して１．２ｇのシダレヤナギ葉抽出物を得た。
【００２６】
また、以下の本発明の実施例において配合した抗炎症剤は、医薬品又は化粧料用として市販されているものを用いた。抗炎症性生薬の抽出物の調製については、次に示す。
【００２７】
［オウゴン抽出物］
オウゴン（Scutellariae Radix）３００ｇを乾燥，粉砕し、エタノール０．５リットル中に加えて２０℃で１０日間静置して抽出し、ろ過してろ液を回収した。このろ液を減圧濃縮し、凍結乾燥したものを標記抽出物とした。
【００２８】
［カンゾウ抽出物］
カンゾウ（Glycyrrhizae Radix）５００ｇを乾燥，粉砕し、熱水１リットル中にて２時間抽出した。ろ過してろ液を回収し、次いで減圧濃縮した後凍結乾燥して、標記抽出物とした。
【００２９】
［クジン抽出物］
クジン（Sophorae Radix）５００ｇを乾燥，粉砕し、５０容量％エタノール水溶液１リットル中に浸漬して、２５℃で７日間抽出した。ろ過してろ液を回収し、標記抽出物とした。
【００３０】
［シャクヤク抽出物］
シャクヤク（Paeoniae Radix）５５０ｇを乾燥，粉砕し、５０容量％エタノール水溶液１リットル中に浸漬して、撹拌しながら２０℃で１０日間抽出した。次いでろ過してろ液を回収し、減圧濃縮した後凍結乾燥して、標記抽出物とした。
【００３１】
［タイソウ抽出物］
タイソウ（Zizyphi Fructus）６００ｇを乾燥，粉砕し、５０容量％エタノール水溶液１リットル中に浸漬して、２５℃で７日間抽出した。ろ過してろ液を回収し、標記抽出物とした。
【００３２】
［ボタンピ抽出物］
ボタンピ（Moutan Cortex）５２０ｇを乾燥，粉砕し、エタノール１リットル中に浸漬して１０℃で１４日間静置し、抽出した。ろ過してろ液を回収し、標記抽出物とした。
【００３３】
［リュウタン抽出物］
リュウタン（Gentianae Scabrae Radix）６５０ｇを乾燥，粉砕し、熱水１リットル中にて４時間抽出した。ろ過してろ液を回収し、減圧濃縮した後凍結乾燥して、標記抽出物とした。
【００３４】
［レンギョウ抽出物］
レンギョウ（Forsythiae Fructus）７５０ｇを粉砕し、1,3-ブチレングリコール１．２リットル中に浸漬して、撹拌しながら１５℃で１０日間抽出した。ろ過してろ液を回収し、標記抽出物とした。
【００３５】
続いて、本発明に係る皮膚外用剤についての実施例の処方を示す。
【００３６】
［実施例１］ ローション剤
（１）エタノール ２０．０（重量％）
（２）ポリオキシエチレン(60E.O.)硬化ヒマシ油 １．０
（３）クロヤナギ樹皮抽出物 １．０
（４）ジプロピレングリコール ５．０
（５）1,3-ブチレングリコール １０．０
（６）グアイアズレンスルホン酸ナトリウム ０．２
（７）パラオキシ安息香酸メチル ０．１
（８）精製水 ６２．７
製法：(８)に(１)〜(７)の成分を順次添加して、溶解，均一化する
【００３７】
［実施例２］ 乳剤
（１）セタノール １．０（重量％）
（２）ミツロウ ０．５
（３）ワセリン ２．０
（４）スクワラン ６．０
（５）ジメチルポリシロキサン ２．０
（６）ポリオキシエチレン(20E.O.)ソルビタン １．０
モノステアリン酸エステル
（７）グリセリルモノステアリン酸エステル １．０
（８）グリセリン ４．０
（９）1,3-ブチレングリコール ４．０
（10）パラオキシ安息香酸メチル ０．１
（11）精製水 ６２．６
（12）カルボキシビニルポリマー １０．０
（１．０重量％水溶液）
（13）水酸化カリウム（１０．０重量％水溶液） １．０
（14）ヨーロッパヤマナラシ葉抽出物 ０．５
（15）アラントイン ０．２
（16）エタノール ５．０
製法：(1)〜(7)の油相成分を混合し、加熱溶解して７５℃とする。一方、(8)〜(11)の水相成分を混合，溶解して７５℃とする。これに前記油相を加えて予備乳化した後、(12)を添加してホモミキサーにて均一に乳化し、次いで(13)を加えて増粘させた後冷却し、４０℃で(14)〜(16)を添加，混合する。
【００３８】
［実施例３］ 乳剤
（１）セタノール １．０（重量％）
（２）ミツロウ ０．５
（３）ワセリン ２．０
（４）スクワラン ６．０
（５）ジメチルポリシロキサン ２．０
（６）ポリオキシエチレン(20E.O.)ソルビタン １．０
モノステアリン酸エステル
（７）グリセリルモノステアリン酸エステル １．０
（８）グリチルレチン酸ステアリル ０．２
（９）グリセリン ４．０
（10）1,3-ブチレングリコール ４．０
（11）パラオキシ安息香酸メチル ０．１
（12）精製水 ６１．９
（13）カルボキシビニルポリマー １０．０
（１．０重量％水溶液）
（14）水酸化カリウム（１０．０重量％水溶液） １．０
（15）エタノール ５．０
（16）オウゴン抽出物 ０．２
（17）ヨーロッパヤナギ樹皮抽出物 ０．１
製法：(1)〜(8)の油相成分を混合し、加熱溶解して７５℃とする。一方、(9)〜(12)の水相成分を混合，溶解して７５℃とする。これに前記油相を加えて予備乳化した後、(13)を添加してホモミキサーにて均一に乳化し、次いで(14)を加えて増粘させた後冷却し、４０℃で(15)〜(17)を加え、混合する。
【００３９】
［実施例４］ 水中油型クリーム剤
（１）ミツロウ ６．００（重量％）
（２）セタノール ５．００
（３）還元ラノリン ８．００
（４）スクワラン ２７．５０
（５）グリチルレチン酸ステアリル ０．０５
（６）グリセリル脂肪酸エステル ４．００
（７）親油型グリセリルモノステアリン酸エステル ２．００
（８）ポリオキシエチレン(20E.O.)ソルビタン ５．００
モノラウリン酸エステル
（９）グリチルレチン酸ステアリル ０．２５
（10）プロピレングリコール ５．００
（11）パラオキシ安息香酸メチル ０．１０
（12）精製水 ３６．８０
（13）シダレヤナギ葉抽出物 ０．１０
（14）カンゾウ抽出物 ０．２０
製法：(１)〜(９)の油相成分を混合，溶解して７５℃とする。一方、(10)〜(12)の水相成分を混合，溶解し、７５℃に加熱する。次いで、この水相成分に前記油相成分を添加して予備乳化した後ホモミキサーにて均一に乳化し、冷却後４０℃にて(13)，及び(14)を添加，混合する。
【００４０】
［実施例５］ 水中油型クリーム剤
（１）ミツロウ ６．０（重量％）
（２）セタノール ５．０
（３）還元ラノリン ８．０
（４）スクワラン ２７．５
（５）グリセリル脂肪酸エステル ４．０
（６）親油型グリセリルモノステアリン酸エステル ２．０
（７）ポリオキシエチレン(20E.O.)ソルビタン ５．０
モノラウリン酸エステル
（８）プロピレングリコール ５．０
（９）パラオキシ安息香酸メチル ０．１
（10）精製水 ３７．０
（11）クロヤナギ樹皮抽出物 ０．３
（12）クジン抽出物 ０．１
製法：(１)〜(７)の油相成分を混合，溶解して７５℃とする。一方、(８)〜(10)の水相成分を混合，溶解し、７５℃に加熱する。次いで、この水相成分に前記油相成分を添加して予備乳化した後ホモミキサーにて均一に乳化し、冷却後４０℃にて(11)，及び(12)を添加，混合する。
【００４１】
［実施例６］ ゲル剤
（１）ジプロピレングリコール １０．０（重量％）
（２）カルボキシビニルポリマー ０．５
（３）パラオキシ安息香酸メチル ０．１
（４）ヨーロッパヤマナラシ葉抽出物 ０．２
（５）シャクヤク抽出物 ０．３
（６）水酸化カリウム（１０．０重量％水溶液） １．０
（７）精製水 ８７．９
製法：(７)に(１)〜(５)を均一に溶解した後、(６)を加えて増粘させる。
【００４２】
［実施例７］ 水中油型乳剤型軟膏
（１）白色ワセリン ２５．０（重量％）
（２）ステアリルアルコール ２５．０
（３）グリセリン １２．０
（４）ラウリル硫酸ナトリウム １．０
（５）パラオキシ安息香酸メチル ０．１
（６）精製水 ３５．８
（７）ヨーロッパヤナギ樹皮抽出物 ０．１
（８）ボタンピ抽出物 １．０
製法：(１)〜(４)の油相成分を混合，加熱して均一に溶解し、７５℃とする。一方、(５)〜(６)の水相成分を混合，加熱して７５℃とする。この水相成分に前記油相成分を撹拌しながら徐々に添加して乳化し、冷却した後、４０℃にて(７)，及び(８)を添加，混合する。
【００４３】
［実施例８］ リポソーム剤
（１）グリセリン ２．０（重量％）
（２）1,3-ブチレングリコール ３．０
（３）ポリオキシエチレン(25E.O.)オレイルエーテル ０．２
（４）エタノール １０．０
（５）パラオキシ安息香酸メチル ０．１
（６）精製水 ７９．７
（７）クロヤナギ樹皮抽出物，カンゾウ ５．０
抽出物内包リポソーム
製法：(５)を(４)に溶解し、(１)〜(３)とともに(６)に添加して均一に混合し、これに(７)を加えて分散する。なお、(７)のクロヤナギ樹皮抽出物，カンゾウ抽出物内包リポソームは、クロヤナギ樹皮抽出物１．０(w/v)％及びカンゾウ抽出物２．０(w/v)％を含有する５０容量％エタノール水溶液１００ｍＬに、大豆レシチン８０ｇを添加して５５℃で懸濁し、次いで超音波処理してリポソームを調製し、遠心分離により回収して得た。
【００４４】
［実施例９］ 油中水型エモリエントクリーム
（１）流動パラフィン ３０．０（重量％）
（２）マイクロクリスタリンワックス ２．０
（３）ワセリン ５．０
（４）ジグリセリルジオレイン酸エステル ５．０
（５）L-グルタミン酸ナトリウム １．６
（６）L-セリン ０．４
（７）プロピレングリコール ３．０
（８）パラオキシ安息香酸メチル ０．１
（９）シダレヤナギ葉抽出物 ０．１
（10）レンギョウ抽出物 １．５
（11）精製水 ５１．２
（12）香料 ０．１
製法：(５)，(６)を(11)の一部に溶解して５０℃とし、あらかじめ５０℃に加温した(４)に撹拌しながら徐々に添加する。これをあらかじめ混合し、７０℃に加熱溶解した(１)〜(３)に均一に分散する。これに、(７)〜(10)を(11)の残部に添加し、７０℃に加熱したものを撹拌しながら加え、ホモミキサーにて乳化する。冷却後、４０℃にて(12)を添加，混合する。
【００４５】
［実施例１０］ メイクアップベースクリーム
（１）ステアリン酸 １２．００（重量％）
（２）セタノール ２．００
（３）グリセリルトリ2-エチルヘキサン酸エステル ２．５０
（４）自己乳化型グリセリルモノステアリン酸 ２．００
エステル
（５）プロピレングリコール １０．００
（６）ヨーロッパヤマナラシ葉抽出物 ０．０２
（７）パラオキシ安息香酸メチル ０．１０
（８）リュウタン抽出物 ０．０５
（９）水酸化カリウム ０．３０
（10）精製水 ６８．４３
（11）酸化チタン ２．００
（12）ベンガラ ０．４０
（13）黄酸化鉄 ０．１０
（14）香料 ０．１０
製法：(１)〜(４)の油相成分を混合，溶解して７５℃とする。一方、(５)〜(10)の水相成分を混合，加熱溶解し、これに(11)〜(13)の顔料成分を添加してホモミキサーにて均一に分散して７５℃とする。次いで、この水相成分に前記油相成分を添加してホモミキサーにて均一に乳化し、冷却後４０℃にて(14)を添加，混合する。
【００４６】
［実施例１１］ 乳液状ファンデーション
（１）ステアリン酸 ２．００（重量％）
（２）スクワラン ５．００
（３）ミリスチン酸オクチルドデシル ５．００
（４）セタノール １．００
（５）デカグリセリルモノイソパルミチン酸エステル ９．００
（６）1,3-ブチレンクリコール ６．００
（７）パラオキシ安息香酸メチル ０．１０
（８）水酸化カリウム ０．０８
（９）精製水 ５２．４７
（10）酸化チタン ９．００
（11）タルク ７．４０
（12）ベンガラ ０．５０
（13）黄酸化鉄 １．１０
（14）黒酸化鉄 ０．１０
（15）ヨーロッパヤナギ樹皮抽出物 ０．１０
（16）タイソウ抽出物 １．００
（17）香料 ０．１５
製法：(１)〜(５)の油相成分を混合，溶解して７５℃とする。一方、(６)〜(９)の水相成分を混合，加熱溶解し、これに(10)〜(14)の顔料成分を添加してホモミキサーにて均一に分散して７５℃とする。次いで、この水相成分に前記油相成分を添加してホモミキサーにて均一に乳化し、冷却後４０℃にて(15)〜(17)を添加，混合する。
【００４７】
［実施例１２］ ハンドクリーム
（１）セタノール ４．００（重量％）
（２）ワセリン ２．００
（３）流動パラフィン １０．００
（４）グリセリルモノステアリン酸エステル １．５０
（５）ポリオキシエチレン(60E.O.)グリセリル ２．５０
イソステアリン酸エステル
（６）酢酸トコフェロール ０．２５
（７）グリセリン ２０．００
（８）パラオキシ安息香酸メチル ０．１０
（９）シダレヤナギ葉抽出物 ０．１０
（10）グリチルリチン酸ジカリウム ０．０２
（11）精製水 ５９．５３
製法：(１)〜(６)の油相成分を混合，溶解して７５℃とする。一方、(７)〜(11)の水相成分を混合，溶解し、７５℃とする。次いで、この水相成分に前記油相成分を添加してホモミキサーにて均一に乳化し、冷却する。
【００４８】
［実施例１３］ パック
（１）精製水 ６９．０（重量％）
（２）ポリビニルアルコール １２．５
（３）エタノール １０．０
（４）グリセリン ５．０
（５）ポリエチレングリコール（平均分子量１５４０） ３．０
（６）クロヤナギ樹皮抽出物 ０．３
（７）カンゾウ抽出物 ０．２
製法：（１）に（２）〜（７）の成分を順次添加して、混合，溶解，均一化する。
【００４９】
［実施例１４］ ヘアートニック
（１）エタノール ５０．０（重量％）
（２）精製水 ４８．４
（３）グリチルリチン酸ジカリウム ０．１
（４）ヨーロッパヤマナラシ葉抽出物 １．５
製法：(１)〜(４)の成分を、混合，均一に溶解する。
【００５０】
［実施例１５］ ヘアーシャンプー
（１）アルキルエーテル硫酸ナトリウム １８．０（重量％）
（２）ヤシ油脂肪酸ジエタノールアミド ２．０
（３）プロピレングリコール ２．０
（４）ヨーロッパヤナギ樹皮抽出物 ０．１
（５）アラントイン ０．１
（６）精製水 ７７．８
製法：（１）〜（５）の成分を順次（６）に添加して、均一とする。
【００５１】
［実施例１６］ ヘアーリンス
（１）セタノール ３．０（重量％）
（２）塩化ステアリルトリメチルアンモニウム ０．７
（３）グリセリン ３．０
（４）N-ココイル-L-アルギニンエチルエステル
-DL-ピロリドンカルボン酸塩 ０．１
（５）アラントイン ０．１
（６）シダレヤナギ葉抽出物 ０．３
（６）精製水 ９２．８
製法：（１）〜（５）の成分を順次（６）に添加して、混合する。
【００５２】
［実施例１７］ 液体ボディシャンプー
（１）N-ラウロイル-L-グルタミン酸 ２０．０（重量％）
トリエタノールアミン（３０．０重量％水溶液）
（２）N-ラウロイルメチルタウリンナトリウム １０．０
（３０．０重量％水溶液）
（３）ラウリン酸トリエタノールアミン １０．０
（４）ミリスチン酸トリエタノールアミン １０．０
（５）ラウロイルイミダゾリニウムベタイン ５．０
（６）ラウロイルジエタノールアミド ５．０
（７）プロピレングリコール ７．０
（８）クロヤナギ樹皮抽出物 １．０
（９）タイソウ抽出物 ０．５
（10）精製水 ４１．５
製法：（１）〜（９）の成分を、順次（10）に添加して、混合する。
【００５３】
［実施例１８］ 洗顔フォーム
（１）ミリスチン酸 １８．０（重量％）
（２）パルミチン酸 ３．０
（３）ステアリン酸 ７．０
（４）混合脂肪酸トリグリセリド ０．１
（５）グリチルレチン酸ステアリル ０．１
（６）自己乳化型モノステアリン酸グリセリン ３．０
（７）精製水 ３８．２
（８）グリセリン １７．０
（９）水酸化カリウム ７．８
（10）ジグリセリン ３．０
（11）1,3-ブチレングリコール １．０
（12）N-ステアロリル-L-グルタミン酸二ナトリウム １．０
（13）パラオキシ安息香酸メチル ０．１
（14）シダレヤナギ葉抽出物 ０．１
（15）グリチルレチン酸ステアリル ０．１
（16）カンゾウ抽出物 ０．５
製法：（１）〜（６）の油相成分を混合，加熱溶解して７０℃とする。（７）〜（16）の水相成分を混合，溶解して７０℃に加熱する。この水相成分に前記油相を徐々に添加してケン化した後、混合しながら冷却する。
【００５４】
上記した本発明に係る実施例のうち、実施例１〜実施例８について、中波長紫外線（ＵＶＢ）による皮膚のしわ形成に対する抑制効果を評価した。その際実施例１〜実施例８において、それぞれ配合したヤナギ科（Salicaceae）植物抽出物及び抗炎症剤、或いはクロヤナギ樹皮抽出物，カンゾウ抽出物内包リポソームを、表１に示すように代替して比較例１〜比較例８とし、同時に評価を行った。評価は、ヘアレスマウス５匹を１群とし、各群について実施例及び比較例をそれぞれ０．２ｇずつ１日１回背部に塗布し、１００ｍＪ／ｃｍ2／回のＵＶＢを１週間に３回、２０週間照射し、ヘアレスマウス皮膚におけるしわの形成状況を観察し、表２に示す判定基準に従って点数化して評価した。この際、精製水のみを塗布した群を対照とした。結果は各群の平均値を算出し、ＵＶＢ照射日数との関係により表３に示した。
【００５５】
【表１】
【表２】
【表３】
表３より明らかなように、対照においては、ＵＶＢ照射日数が１０週を越える頃には皮膚に形成されたしわの深さは中程度にまで達し、２０週後には深いしわの形成が認められていた。有効成分として、ヤナギ科（Salicaceae）植物抽出物のみを含有する比較例１及び比較例６塗布群では、２０週後に軽微なしわの形成が認められる程度で、しわの形成は良好に抑制されており、また抗炎症剤を含有し、ヤナギ科（Salicaceae）植物抽出物を含有しない他の比較例塗布群でも、対照に比べてしわ形成に対する抑制効果は認められていたが、それぞれ対応する実施例塗布群では、いずれも２０週後に微小なしわの形成が認められた程度で、それぞれ対応する比較例塗布群に比べて、しわ形成に対する抑制効果は有意に向上していた。
【００５９】
続いて、本発明の実施例１〜実施例１３について使用試験を行い、皮膚の老化症状の改善効果を評価した。その際、実施例９〜実施例１３において、配合したヤナギ科（Salicaceae）植物抽出物及び抗炎症剤を表４に示すように代替して比較例９〜比較例１３とし、上記比較例１〜比較例８とともに同時に使用試験に供した。
【００６０】
【表４】
皮膚の老化症状の改善効果は、小じわ形成及び皮膚弾性の低下が顕著に認められる４０才代〜６０才代の女性パネラー２０名を１群とし、各群に実施例及び比較例のそれぞれをブラインドにて１日２回、２カ月間連続して使用させて評価した。小じわの程度については肉眼観察及び写真撮影により評価し、皮膚弾性についてはキュートメーターにより測定して、それぞれ使用試験開始前及び終了後の状態を比較し、「改善」，「やや改善」，「変化なし」の３段階で評価した。結果は、各評価を得たパネラー数にて表５に示した。
【００６２】
【表５】
表５より明らかなように、有効成分として抗炎症剤を含有するがヤナギ科（Salicaceae）植物抽出物を含有しない比較例２〜比較例５，比較例７，比較例８及び比較例１０〜比較例１２の各使用群においては、小じわ及び皮膚弾性の改善傾向は認められるものの、明確な改善を認めたパネラーはさほど多くなかった。ヤナギ科（Salicaceae）植物抽出物のみを含有する比較例１，比較例６，比較例９，比較例１３の各使用群のそれぞれにおいては、かなり良好な小じわ及び皮膚弾性の改善傾向が認められていたが、実施例使用群においては、それぞれ対応する比較例使用群に比べて、明確な改善を認めたパネラーは有意に多くなっていた。
【００６４】
また、本発明の実施例１〜実施例１３及び比較例１〜比較例１３について、肌荒れ症状の改善効果を評価した。肌荒れ症状の改善効果は、顕著な肌荒れ症状を呈する２０才代〜６０才代の女性パネラー２０名を１群とし、各群に実施例及び比較例のそれぞれをブラインドにて１日２回、２カ月間連続して使用させて評価した。使用試験開始前及び終了後の皮膚の状態を、表６に示す評価基準に従って評価，点数化し、２０名の平均値を算出して表７に示した。
【００６５】
【表６】
【表７】
表７より明らかなように、本発明の実施例使用群ではいずれにおいても顕著な肌荒れの改善が認められ、使用試験終了後において、皮膚の状態はほぼ良好〜良好な状態にまで改善されていた。これに対し比較例使用群においても、かなり良好な肌荒れの改善が認められていたが、その程度はそれぞれ対応する実施例使用群に比べて小さいものであった。
【００６８】
なお実施例１〜実施例１３については、２５℃で６カ月間保存した場合において状態の変化は全く認められず、男性パネラー３０名による４８時間の背部閉塞貼付試験においても、問題となる皮膚刺激性反応は認められなかった。
【００６９】
【発明の効果】
以上詳述したように、本発明により、安定性及び安全性が良好で、肌荒れ及び皮膚の老化の防止，改善効果が相乗的に向上した皮膚外用剤を得ることができた。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an external preparation for skin which synergistically improves the effect of preventing and improving rough skin and aging of the skin. For more details, willow family (S0alicaceae) It relates to a skin external preparation comprising a combination of a plant extract and an anti-inflammatory agent.
[0002]
[Prior art]
It is known that inflammatory reaction of the skin and aging of the skin progress due to aging, exposure to ultraviolet rays, oxidative stress due to reactive oxygen species generated in the skin tissue, contact with drugs and various allergens, and the like. In the field of topical skin preparations, many physiologically active ingredients such as reactive oxygen species scavengers, anti-inflammatory agents, and antiallergic agents have been searched and examined in order to prevent inflammation and aging of the skin. In addition, as it becomes clear that aging symptoms of skin progress due to modification of collagen, which is a component of the dermis matrix, due to aging and stress, studies on substances that have the effect of promoting their production in skin tissue Has been made. In recent years, there has been an increasing tendency to demand such components from plants, reflecting the natural and plant orientation of consumers.
[0003]
However, among the above-mentioned ingredients of plant origin that have already been reported, the activity is low, so that a considerably high concentration is required to obtain a sufficient action effect when blended with an external preparation for skin, stability or safety. When there are problems with sexuality, or there are things that give unfavorable color or odor to the external preparation for skin, when blended with external preparation for skin, all of the stability and safety of the preparation, and the action effect There are few things that can be satisfied in terms of the situation. In addition, since the inflammatory reaction and aging of the skin proceed with various factors involved in a complicated manner, sufficient effects cannot be obtained even if a substance that acts only on a part of the reaction is used.
[0004]
[Problems to be solved by the invention]
Accordingly, an object of the present invention is to obtain an external preparation for skin that suppresses complex skin inflammatory reactions and the like, and synergistically improves the effect of preventing and improving rough skin and aging of the skin.
[0005]
[Means for Solving the Problems]
As a result of various studies to solve the above-mentioned problems, the present inventors have studied the willow family (Salicaceae) By using a plant extract and one or more anti-inflammatory agents in combination in an external preparation for skin, the prevention of rough skin and aging of the skin, and a synergistic improvement in the improvement effect can be obtained. As a result, the present invention has been completed.
[0006]
Willow family (Salicaceae) Regarding the effectiveness of the plant extract, the whitening effect of dihydromyricenan contained in leaves (Japanese Patent Laid-Open No. Sho 63-316711) and the antimutagenic action (Japanese Patent Laid-Open No. 1-175932), and the histamine release inhibitory action of bark extract ( JP-A-10-287582), the fibroblast activation action of salicin contained in a large amount in bark and leaves (JP-A-11-80002) and the like are already known.
[0007]
In addition, anti-inflammatory agents have long been blended in topical skin preparations in the hope of improving skin roughness.Salicaceae) The effect of the present invention obtained by using a plant extract and an anti-inflammatory agent in combination has not been suggested at all.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Willows used in the present invention (Salicaceae) Plants include Pepper willow (Pepper willow)Chosenia arbutifolia (Pallas) A. Skvortz;Chosenia bracteosa Nakai), the willow tree (Yamanashi, Poplar) genusPopulus sieboldi Miq.), Dero (Dronoki) (Populus maxmowiczii Henry), Vulgarine Willow (Gindro) (Populus alba L.), American black willow (Populus deltoides Marsh .;Populus monilifera Ait.;Populus angulata Aiv.), Kotoka willow (Populus euphratica Oliv.), European black porcupine (Populus nigra L.), boxwood willow (Populus nigra var.italica Koehne), European Porcupine (Populus tremula), Willow genus caspian willow (Salix acutifolia L.), European willow (Salix alba L .;Salix aurea Salisb.), Weeping willowSalix babylonica L.), Wildcat Willow (Bacco willow) (Salix bakko Kimura), red willow (Salix chaenomeloides Kimura), Nagabagawa Willow (Salix gilgiana Seemen.), Pussy willow (Enocoro willow, kawa willow) (Salix gracilistyla Miq.), Inukoryanagi (Salix integra Thunb.), Shibanagi (Salix japonica Thunb.), Kinuyanagi (Salix kinuyanagi Kimura), Koryanagi (Salix koriyanagi Kimura;Salix purpurea var.japonica Nakai), Friso de willow (Salix leucopithecia Kimura), Unryu willow (Salix matsudana Koidz.), Takane willow (Rengei willow) (Salix nakamurana Koidz.), Black Willow (Salix nigra), Purple willow (Salix purpurea L.), Onoe willowSalix sachalinensis Fr. Schm.), Miyama willow (Mine willow) (Salix reinii Fr. et Sav.), Yamanagi (Salix sieboldiana Bl.)(Salix viminalis L.;Salix longifolia Lam.), Fox willowSalix vulpina), The willow genusToisusu urbaniana ;Salix urbaniana) Etc. are exemplified. Among these, in particular, the European porcupine (Populus tremula), European willow (Salix alba L.;Salix aurea Salisb.), Weeping willowSali x babylonica L.), black willow (Salix nigra), Purple willow (Salix purpurea It is preferable to use one or more plants selected from L.), andSalix nigra) Bark extract is most preferred. Willow family (Salicaceae) Although the site | part at the time of obtaining an extract from a plant is not specifically limited, A bark, a leaf, and a female flower are used preferably from the point of the antibacterial action.
[0009]
These willows (Salicaceae) As an extraction solvent for obtaining plant extracts, water, ethanol, methanol, isopropanol, isobutanol, n-hexanol, methyl amyl alcohol, 2-ethylbutanol, alcohols such as n-octyl alcohol, glycerin, ethylene glycol, Polyhydric alcohols such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, propylene glycol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, triethylene glycol, 1,3-butylene glycol, hexylene glycol or derivatives thereof, acetone, Ketones such as methyl ethyl ketone, methyl isobutyl ketone and methyl-n-propyl ketone, esters such as ethyl acetate and isopropyl acetate, ethyl ether, iso One or more mixed solvents selected from polar solvents such as ethers such as propyl ether and n-butyl ether can be suitably used, and phosphate buffered saline can also be used. There is no limitation. For the purpose of the present invention, a polar solvent is preferable from the viewpoint of antibacterial activity, and further, one or more mixed solvents selected from methanol, ethanol, 1,3-butylene glycol and water, particularly water, are used. It is preferable to use a solvent.
[0010]
Extraction methods include extraction by soaking in a cooled or warm state at room temperature, extraction using a distillation method such as steam distillation, raw willows (Salicaceae) The pressing method etc. which squeeze from a plant and obtain an extract etc. are illustrated, These methods are extracted individually or in combination of 2 or more types.
[0011]
Willows during extraction (Salicaceae) The ratio of plant to solvent is not particularly limited, but willowaceae (Salicaceae) The solvent is preferably 0.5 to 1000 times by weight of the plant 1, particularly 0.5 to 100 times by weight in terms of extraction operation and efficiency. The extraction temperature is conveniently in the range from room temperature to the boiling point of the solvent under normal pressure, and the extraction time is preferably in the range of 2 hours to 2 weeks, although it varies depending on the extraction temperature.
[0012]
The willow family thus obtained (Salicaceae) The plant extract can be used as it is, but it can be purified by adding purification operations such as deodorization, decolorization and concentration within the range not losing the antibacterial action of the present invention, and further using column chromatography or the like. It may be used as a painting. These extracts, purified products, and fractions can be dried by removing the solvent from them, and can be provided in a form solubilized in a solvent such as alcohol, or in the form of an emulsion. it can.
[0013]
In the present invention, the willow family (Salicaceae) Anti-inflammatory agents used in combination with plant extracts include cortisone, hydrocortisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, beclomethasone and their phosphates, propionic acid Steroidal anti-inflammatory agents such as salts, acetates and succinates, salicylic acid derivatives such as salicylic acid and aspirin, salicylamide, etenzamide, methyl salicylate, indoleacetic acid derivatives such as indomethacin, sulindac, phenylbutazone, oxyphenbutazone, etc. Pyrazolidinedione derivatives, anthranilic acid derivatives such as mefenamic acid and flufenamic acid, propionic acid derivatives such as ibuprofen, ketoprofen and naproxen, diclof Non-steroidal anti-inflammatory agents such as phenylacetic acid derivatives such as nac, fenbufen and bufexamac, benzothiazine derivatives such as piroxicam, salts and derivatives of glycyrrhizic acid such as dipotassium glycyrrhizinate and glycyrrhizinate, monoammonium glycyrrhizinate, glycyrrhetinic acid and stearyl glycyrrhetinate , Glycyrrhetinic acid salts such as glycyrrhetinyl stearate, disodium 3-succinyloxyglycyrrhetinic acid, and derivatives, azulene derivatives such as guaiazulene, ethyl guaiazulene sulfonate, sodium guaiazulene sulfonate, camazulene, allantoin, aloin, aloe emodin, shikonin and isobutyl shikonin , Acetyl shikonin, isovaleryl shikonin and other shikonin derivatives, ginsenoside Ra1, Ginsenoside Ra2, Ginsenoside Rb1Such as ginsenoside, and 20-glucoginsenoside RfAnd geonsenoside derivatives such as peoniflorin, peonol, and peonol derivatives such as peonoside and peonolide.
[0014]
In the present invention, as an anti-inflammatory agent,Scutellariae Radix), Daylily (Glycyrrhizae Radix), Kujin (Sophorae Radix), Psycho (Bupleuri Radix), Peony (Paeoniae Radix), Shouma (Cimicifugae Rhizoma), Tissou (Zizyphi Fructus), Chimo (Anemarrhenae Rhizoma), Button pi (Moutan Cortex), Ryutan (Gentianae Scabrae Radix), Forsythia (Forsythiae Fructus), Etc., and herbal medicines used as anti-inflammatory agents or extracts thereof can also be used.
[0015]
For the external preparation for skin according to the present invention, one or more of these anti-inflammatory agents are selected and used.
[0016]
As the anti-inflammatory agent in the present invention, one or more selected from glycyrrhizic acid salts and derivatives, glycyrrhetinic acid salts and derivatives, and liquorice are preferably used because of their ease of incorporation into an external preparation for skin. From the viewpoint of the effect of improving skin roughness, it is preferable to use one or two selected from stearyl glycyrrhetinate and licorice extract.
[0017]
In the present invention, the willow family (Salicaceae) A plant extract and one or more anti-inflammatory agents are contained in a skin external preparation base. For the total amount of the topical skin preparation,SalicaceaeIt is appropriate that the plant extract is about 0.001 to 5.0% by weight. The anti-inflammatory agent varies depending on the type, but is appropriately about 0.0001 to 5.0% by weight.
[0018]
The external preparation for skin according to the present invention can be provided in various dosage forms such as lotions, emulsions, gels, creams, ointments, powders, granules and the like. Also, skin cosmetics such as lotion, milky lotion, cream, cosmetic liquid, packs, foundation cosmetics such as makeup base lotion and makeup base cream, foundations for each dosage form such as emulsion, oily, solid, etc. It can be provided as makeup cosmetics such as color and teak color, and body cosmetics such as hand cream, leg cream, neck cream and body lotion.
[0019]
In addition, the topical skin preparation according to the present invention includes a willow family (Salicaceae) In addition to plant extracts and anti-inflammatory agents, general pharmaceutical and cosmetic raw materials such as oil components, surfactants, moisturizers, pigments, UV absorbers, antioxidants, fragrances, antifungal agents, etc. In addition, physiologically active ingredients such as a skin cell activator and a whitening agent can be contained.
[0020]
【Example】
Further, the features of the present invention will be described in detail with reference to examples.
[0021]
First, the willow family (in the skin external preparation according to the present invention)Salicaceae) Preparation of plant extract is shown.
[0022]
[Black willow bark extract]
Black willows collected in spring (Salix nigra(2) 1000 g of purified water is added to a piece of 200 g of fresh bark, and extracted for 36 hours with stirring at 25 ° C. The obtained extract was filtered and concentrated under reduced pressure to obtain 150 g of black willow bark extract.
[0023]
[European porcupine leaf extract]
European Porcupine (Populus tremula) After adding 200 g of fresh leaves, add 1000 g of purified water and extract at 25 ° C. with stirring for 36 hours. The obtained extract was filtered and then concentrated under reduced pressure to obtain 120 g of a European porcupine leaf extract.
[0024]
[European willow bark extract]
Dried European willow (Salix alba L.;Salix aurea Salisb.) 50 g is ground, 1000 g of 50 vol% ethanol is added and extracted for 24 hours at room temperature. The obtained extract was filtered, concentrated under reduced pressure, and freeze-dried to obtain 5 g of a European willow bark extract.
[0025]
[Weeping willow leaf extract]
Fresh weeping willowSalix babylonica L.) Add 100 g of purified water to 10 g of shoots, and stir and extract with a mixer for 10 minutes. The obtained extract was filtered, concentrated under reduced pressure, and lyophilized to obtain 1.2 g of weeping willow leaf extract.
[0026]
Moreover, what was marketed as a pharmaceutical or cosmetics was used for the anti-inflammatory agent mix | blended in the following Example of this invention. The preparation of the anti-inflammatory crude drug extract is described below.
[0027]
[Ougon extract]
Ougon (Scutellariae Radix) 300 g was dried and pulverized, added to 0.5 liter of ethanol, left to stand at 20 ° C. for 10 days for extraction, and filtered to collect the filtrate. The filtrate was concentrated under reduced pressure and lyophilized to give the title extract.
[0028]
[Licorice extract]
Daylily (Glycyrrhizae Radix) 500 g was dried, ground and extracted in 1 liter of hot water for 2 hours. The filtrate was collected by filtration, then concentrated under reduced pressure and then lyophilized to obtain the title extract.
[0029]
[Cuzin extract]
Kujin (Sophorae Radix) 500 g was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution and extracted at 25 ° C. for 7 days. The filtrate was collected by filtration and used as the title extract.
[0030]
[Peonies extract]
Peonies (Paeoniae Radix) 550 g was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution, and extracted at 20 ° C. for 10 days with stirring. The filtrate was then collected by filtration, concentrated under reduced pressure, and lyophilized to give the title extract.
[0031]
[Tithus extract]
Taisou (Zizyphi Fructus) 600 g was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution and extracted at 25 ° C. for 7 days. The filtrate was collected by filtration and used as the title extract.
[0032]
[Button pi extract]
Button pin (Moutan Cortex) 520 g was dried, pulverized, immersed in 1 liter of ethanol, left to stand at 10 ° C. for 14 days, and extracted. The filtrate was collected by filtration and used as the title extract.
[0033]
[Ryutan extract]
Ryutan (Gentianae Scabrae Radix) 650 g was dried, ground and extracted in 1 liter of hot water for 4 hours. The filtrate was collected by filtration, concentrated under reduced pressure, and lyophilized to give the title extract.
[0034]
[Forsythia extract]
Forsythia (Forsythiae Fructus) 750 g was pulverized, immersed in 1.2 liters of 1,3-butylene glycol, and extracted for 10 days at 15 ° C. with stirring. The filtrate was collected by filtration and used as the title extract.
[0035]
Then, the prescription of the Example about the skin external preparation which concerns on this invention is shown.
[0036]
[Example 1] Lotion
(1) Ethanol 20.0 (% by weight)
(2) Polyoxyethylene (60E.O.) hydrogenated castor oil 1.0
(3) Black Willow Bark Extract 1.0
(4) Dipropylene glycol 5.0
(5) 1,3-butylene glycol 10.0
(6) Sodium guaiazulene sulfonate 0.2
(7) Methyl paraoxybenzoate 0.1
(8) Purified water 62.7
Manufacturing method: Add components (1) to (7) sequentially to (8) to dissolve and homogenize
[0037]
Example 2 Emulsion
(1) Cetanol 1.0 (% by weight)
(2) Beeswax 0.5
(3) Vaseline 2.0
(4) Squalane 6.0
(5) Dimethylpolysiloxane 2.0
(6) Polyoxyethylene (20E.O.) sorbitan 1.0
Monostearic acid ester
(7) Glyceryl monostearate ester 1.0
(8) Glycerin 4.0
(9) 1,3-butylene glycol 4.0
(10) Methyl paraoxybenzoate 0.1
(11) Purified water 62.6
(12) Carboxyvinyl polymer 10.0
(1.0 wt% aqueous solution)
(13) Potassium hydroxide (10.0 wt% aqueous solution) 1.0
(14) European porcupine leaf extract 0.5
(15) Allantoin 0.2
(16) Ethanol 5.0
Production method: The oil phase components (1) to (7) are mixed and dissolved by heating to 75 ° C. On the other hand, the water phase components (8) to (11) are mixed and dissolved to 75 ° C. After preliminarily emulsifying by adding the oil phase to this, (12) was added and uniformly emulsified with a homomixer, and then (13) was added to increase the viscosity, followed by cooling at 40 ° C. (14) Add ~ 16 and mix.
[0038]
Example 3 Emulsion
(1) Cetanol 1.0 (% by weight)
(2) Beeswax 0.5
(3) Vaseline 2.0
(4) Squalane 6.0
(5) Dimethylpolysiloxane 2.0
(6) Polyoxyethylene (20E.O.) sorbitan 1.0
Monostearic acid ester
(7) Glyceryl monostearate ester 1.0
(8) Stearyl glycyrrhetinate 0.2
(9) Glycerin 4.0
(10) 1,3-butylene glycol 4.0
(11) Methyl paraoxybenzoate 0.1
(12) Purified water 61.9
(13) Carboxyvinyl polymer 10.0
(1.0 wt% aqueous solution)
(14) Potassium hydroxide (10.0 wt% aqueous solution) 1.0
(15) Ethanol 5.0
(16) Ogon extract 0.2
(17) European willow bark extract 0.1
Production method: The oil phase components (1) to (8) are mixed and dissolved by heating to 75 ° C. On the other hand, the aqueous phase components (9) to (12) are mixed and dissolved to 75 ° C. After preliminarily emulsifying by adding the oil phase to this, (13) was added and uniformly emulsified with a homomixer, and then (14) was added to increase the viscosity, followed by cooling at 40 ° C. (15) Add ~ (17) and mix.
[0039]
[Example 4] Oil-in-water cream
(1) Beeswah 6.00 (wt%)
(2) Cetanol 5.00
(3) Reduced lanolin 8.00
(4) Squalane 27.50
(5) Stearyl glycyrrhetinate 0.05
(6) Glyceryl fatty acid ester 4.00
(7) Lipophilic glyceryl monostearate 2.00
(8) Polyoxyethylene (20E.O.) sorbitan 5.00
Monolaurate
(9) Stearyl glycyrrhetinate 0.25
(10) Propylene glycol 5.00
(11) Methyl paraoxybenzoate 0.10
(12) Purified water 36.80
(13) Weeping willow leaf extract 0.10
(14) Licorice extract 0.20
Production method: The oil phase components (1) to (9) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (10) to (12) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the water phase component and pre-emulsified, and then uniformly emulsified with a homomixer. After cooling, (13) and (14) are added and mixed at 40 ° C.
[0040]
[Example 5] Oil-in-water cream
(1) Beeswaw 6.0 (wt%)
(2) Cetanol 5.0
(3) Reduced lanolin 8.0
(4) Squalane 27.5
(5) Glyceryl fatty acid ester 4.0
(6) Lipophilic glyceryl monostearate 2.0
(7) Polyoxyethylene (20E.O.) sorbitan 5.0
Monolaurate
(8) Propylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 37.0
(11) Black willow bark extract 0.3
(12) Kujin extract 0.1
Production method: The oil phase components (1) to (7) are mixed and dissolved to 75 ° C. On the other hand, the water phase components (8) to (10) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the aqueous phase component and pre-emulsified, and then uniformly emulsified with a homomixer. After cooling, (11) and (12) are added and mixed at 40 ° C.
[0041]
[Example 6] Gel agent
(1) Dipropylene glycol 10.0 (% by weight)
(2) Carboxyvinyl polymer 0.5
(3) Methyl paraoxybenzoate 0.1
(4) European porcupine leaf extract 0.2
(5) Peonies extract 0.3
(6) Potassium hydroxide (10.0 wt% aqueous solution) 1.0
(7) Purified water 87.9
Production method: (1) to (5) are uniformly dissolved in (7), and then (6) is added to increase the viscosity.
[0042]
[Example 7] Oil-in-water emulsion type ointment
(1) White petrolatum 25.0 (% by weight)
(2) Stearyl alcohol 25.0
(3) Glycerin 12.0
(4) Sodium lauryl sulfate 1.0
(5) Methyl paraoxybenzoate 0.1
(6) Purified water 35.8
(7) European willow bark extract 0.1
(8) Button pi extract 1.0
Production method: The oil phase components (1) to (4) are mixed and heated to dissolve uniformly to 75 ° C. On the other hand, the aqueous phase components (5) to (6) are mixed and heated to 75 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify, and after cooling, (7) and (8) are added and mixed at 40 ° C.
[0043]
[Example 8] Liposome agent
(1) Glycerin 2.0 (% by weight)
(2) 1,3-butylene glycol 3.0
(3) Polyoxyethylene (25E.O.) oleyl ether 0.2
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Purified water 79.7
(7) Black Willow Bark Extract, Daylily 5.0
Extract-encapsulated liposome
Production method: Dissolve (5) in (4), add to (6) together with (1) to (3), mix uniformly, add (7) to this and disperse. In addition, (7) black willow bark extract and licorice extract-encapsulating liposomes contain 50 vol% containing black willow bark extract 1.0 (w / v)% and licorice extract 2.0 (w / v)%. To 100 mL of an aqueous ethanol solution, 80 g of soybean lecithin was added and suspended at 55 ° C., followed by sonication to prepare liposomes, which were collected by centrifugation.
[0044]
[Example 9] Water-in-oil emollient cream
(1) Liquid paraffin 30.0 (wt%)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglyceryl dioleate 5.0
(5) Sodium L-glutamate 1.6
(6) L-serine 0.4
(7) Propylene glycol 3.0
(8) Methyl paraoxybenzoate 0.1
(9) Weeping willow leaf extract 0.1
(10) Forsythia extract 1.5
(11) Purified water 51.2
(12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C., and gradually add to (4) heated in advance to 50 ° C. with stirring. This is mixed in advance and uniformly dispersed in (1) to (3) heated and dissolved at 70 ° C. (7) to (10) are added to the remainder of (11), and the mixture heated to 70 ° C. is added with stirring and emulsified with a homomixer. After cooling, add and mix (12) at 40 ° C.
[0045]
[Example 10] Makeup base cream
(1) Stearic acid 12.00 (% by weight)
(2) Cetanol 2.00
(3) Glyceryl tri-2-ethylhexanoate 2.50
(4) Self-emulsifying glyceryl monostearic acid 2.00
ester
(5) Propylene glycol 10.00
(6) European porcupine leaf extract 0.02
(7) Methyl paraoxybenzoate 0.10
(8) Ryutan extract 0.05
(9) Potassium hydroxide 0.30
(10) Purified water 68.43
(11) Titanium oxide 2.00
(12) Bengala 0.40
(13) Yellow iron oxide 0.10
(14) Fragrance 0.10
Production method: The oil phase components (1) to (4) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (5) to (10) are mixed, dissolved by heating, and the pigment components (11) to (13) are added thereto and dispersed uniformly with a homomixer to 75 ° C. Next, the oil phase component is added to the water phase component, and the mixture is uniformly emulsified with a homomixer. After cooling, (14) is added and mixed at 40 ° C.
[0046]
[Example 11] Emulsion foundation
(1) Stearic acid 2.00 (wt%)
(2) Squalane 5.00
(3) Octyl dodecyl myristate 5.00
(4) Cetanol 1.00
(5) Decaglyceryl monoisopalmitate 9.00
(6) 1,3-Butylenecricol 6.00
(7) Methyl paraoxybenzoate 0.10
(8) Potassium hydroxide 0.08
(9) Purified water 52.47
(10) Titanium oxide 9.00
(11) Talc 7.40
(12) Bengala 0.50
(13) Yellow iron oxide 1.10.
(14) Black iron oxide 0.10
(15) European willow bark extract 0.10
(16) Isolate extract 1.00
(17) Fragrance 0.15
Production method: The oil phase components (1) to (5) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (6) to (9) are mixed, dissolved by heating, the pigment components (10) to (14) are added thereto, and the mixture is uniformly dispersed with a homomixer to 75 ° C. Next, the oil phase component is added to the aqueous phase component, and the mixture is uniformly emulsified with a homomixer. After cooling, (15) to (17) are added and mixed at 40 ° C.
[0047]
[Example 12] Hand cream
(1) Cetanol 4.00 (wt%)
(2) Vaseline 2.00
(3) Liquid paraffin 10.00
(4) Glyceryl monostearate 1.50
(5) Polyoxyethylene (60E.O.) glyceryl 2.50
Isostearic acid ester
(6) Tocopherol acetate 0.25
(7) Glycerin 20.00
(8) Methyl paraoxybenzoate 0.10
(9) Weeping willow leaf extract 0.10
(10) Dipotassium glycyrrhizinate 0.02
(11) Purified water 59.53
Production method: The oil phase components (1) to (6) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (7) to (11) are mixed and dissolved to 75 ° C. Next, the oil phase component is added to the aqueous phase component, and the mixture is uniformly emulsified with a homomixer and cooled.
[0048]
[Example 13] Pack
(1) Purified water 69.0 (% by weight)
(2) Polyvinyl alcohol 12.5
(3) Ethanol 10.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1540) 3.0
(6) Black willow bark extract 0.3
(7) Licorice extract 0.2
Production method: Components (2) to (7) are sequentially added to (1) to mix, dissolve and homogenize.
[0049]
[Example 14] Hair Nick
(1) Ethanol 50.0 (% by weight)
(2) Purified water 48.4
(3) Dipotassium glycyrrhizinate 0.1
(4) European porcupine leaf extract 1.5
Production method: Components (1) to (4) are mixed and dissolved uniformly.
[0050]
[Example 15] Hair shampoo
(1) Sodium alkyl ether sulfate 18.0 (% by weight)
(2) Palm oil fatty acid diethanolamide 2.0
(3) Propylene glycol 2.0
(4) European willow bark extract 0.1
(5) Allantoin 0.1
(6) Purified water 77.8
Production method: Components (1) to (5) are added to (6) sequentially to make uniform.
[0051]
[Example 16] Hair rinse
(1) Cetanol 3.0 (% by weight)
(2) Stearyltrimethylammonium chloride 0.7
(3) Glycerin 3.0
(4) N-cocoyl-L-arginine ethyl ester
-DL-pyrrolidonecarboxylate 0.1
(5) Allantoin 0.1
(6) Weeping willow leaf extract 0.3
(6) Purified water 92.8
Production method: Components (1) to (5) are sequentially added to (6) and mixed.
[0052]
[Example 17] Liquid body shampoo
(1) N-lauroyl-L-glutamic acid 20.0 (% by weight)
Triethanolamine (30.0 wt% aqueous solution)
(2) N-lauroylmethyl taurine sodium 10.0
(30.0 wt% aqueous solution)
(3) lauric acid triethanolamine 10.0
(4) Triethanolamine myristic acid 10.0
(5) Lauroi imidazolinium betaine 5.0
(6) Lauroyl diethanolamide 5.0
(7) Propylene glycol 7.0
(8) Black Willow Bark Extract 1.0
(9) Isolate extract 0.5
(10) Purified water 41.5
Production method: Components (1) to (9) are added to (10) sequentially and mixed.
[0053]
[Example 18] Facial cleansing foam
(1) Myristic acid 18.0 (wt%)
(2) Palmitic acid 3.0
(3) Stearic acid 7.0
(4) Mixed fatty acid triglyceride 0.1
(5) Stearyl glycyrrhetinate 0.1
(6) Self-emulsifying glyceryl monostearate 3.0
(7) Purified water 38.2
(8) Glycerin 17.0
(9) Potassium hydroxide 7.8
(10) Diglycerin 3.0
(11) 1,3-butylene glycol 1.0
(12) Disodium N-stearolyl-L-glutamate 1.0
(13) Methyl paraoxybenzoate 0.1
(14) Weeping willow leaf extract 0.1
(15) Stearyl glycyrrhetinate 0.1
(16) Licorice extract 0.5
Production method: The oil phase components (1) to (6) are mixed, heated and dissolved to 70 ° C. The aqueous phase components (7) to (16) are mixed, dissolved, and heated to 70 ° C. The oil phase is gradually added to the aqueous phase component to saponify it, and then cooled while mixing.
[0054]
Among the examples according to the present invention described above, Examples 1 to 8 were evaluated for the effect of suppressing wrinkle formation on the skin by medium wavelength ultraviolet rays (UVB). At that time, in Examples 1 to 8, each of the willows (Salicaceae) The plant extract and anti-inflammatory agent, or the black willow bark extract and the liquorice extract-encapsulating liposome were replaced as shown in Table 1 to be Comparative Examples 1 to 8 and evaluated at the same time. The evaluation was carried out on a back part of 0.2g each of Examples and Comparative Examples for each group of 5 hairless mice, 100 mJ / cm.2UVB was irradiated 3 times a week for 20 weeks, and the state of wrinkle formation in the hairless mouse skin was observed and scored according to the criteria shown in Table 2 for evaluation. At this time, a group to which only purified water was applied was used as a control. As a result, the average value of each group was calculated and shown in Table 3 according to the relationship with the number of days of UVB irradiation.
[0055]
[Table 1]
[Table 2]
[Table 3]
As is clear from Table 3, in the control, when the UVB irradiation days exceeded 10 weeks, the depth of wrinkles formed in the skin reached a medium level, and after 20 weeks, formation of deep wrinkles was observed. It was. As an active ingredient, willow family (Salicaceae) In Comparative Example 1 and Comparative Example 6 application group containing only plant extract, wrinkle formation was well suppressed to the extent that slight wrinkle formation was observed after 20 weeks, and also contained anti-inflammatory agent And willow family (Salicaceae) In other comparative example application groups containing no plant extract, the inhibitory effect on wrinkle formation was recognized as compared with the control, but in each of the corresponding example application groups, formation of fine wrinkles after 20 weeks. As compared with the corresponding comparative application groups, the effect of suppressing wrinkle formation was significantly improved.
[0059]
Then, the use test was done about Example 1-Example 13 of this invention, and the improvement effect of the skin aging symptom was evaluated. At that time, in the examples 9 to 13, the willow family (Salicaceae) The plant extract and the anti-inflammatory agent were substituted as shown in Table 4 to give Comparative Examples 9 to 13, which were used in the usage test together with the above Comparative Examples 1 to 8.
[0060]
[Table 4]
The effect of improving skin aging symptoms is that 20 female panelists in their 40's to 60's in which fine wrinkle formation and skin elasticity are remarkably observed are defined as one group, and each of the examples and comparative examples is blinded in each group. And used continuously twice a day for 2 months. The degree of fine lines is evaluated by visual observation and photography, and the skin elasticity is measured by a cut meter, and the state before and after the use test is started and compared, and "improvement", "slight improvement", "change" It was evaluated in three stages, “none”. The results are shown in Table 5 as the number of panelists that obtained each evaluation.
[0062]
[Table 5]
As is apparent from Table 5, an anti-inflammatory agent is contained as an active ingredient, but the willow family (Salicaceae) In each use group of Comparative Example 2 to Comparative Example 5, Comparative Example 7, Comparative Example 8 and Comparative Example 10 to Comparative Example 12 containing no plant extract, fine wrinkles and an improvement tendency of skin elasticity were observed, but clearly There were not so many panelists who recognized the improvement. Willow family (Salicaceae) In each of the use groups of Comparative Example 1, Comparative Example 6, Comparative Example 9, and Comparative Example 13 containing only plant extract, fairly good wrinkles and a tendency to improve skin elasticity were observed. In the case use group, the number of panelists who showed a clear improvement was significantly greater than in the corresponding comparative example use group.
[0064]
Moreover, the improvement effect of the rough skin symptom was evaluated about Example 1- Example 13 and Comparative Example 1- Comparative Example 13 of this invention. The improvement effect of rough skin symptoms is a group of 20 female panelists in their 20s to 60s who show remarkable rough skin symptoms, and each of the examples and comparative examples is blinded twice a day. Evaluated by using continuously for months. The skin condition before and after the start of the use test was evaluated and scored according to the evaluation criteria shown in Table 6, and the average value of 20 people was calculated and shown in Table 7.
[0065]
[Table 6]
[Table 7]
As is clear from Table 7, in the examples using groups of the present invention, remarkable improvement in rough skin was observed in all cases, and after completion of the use test, the skin condition was improved from almost good to good. . On the other hand, in the comparative example use group, a considerably good improvement in rough skin was observed, but the degree was smaller than the corresponding example use group.
[0068]
In Examples 1 to 13, no change in state was observed when stored at 25 ° C. for 6 months, and skin irritation was problematic even in a 48-hour back obstruction patch test by 30 male panelists. Sexual reaction was not observed.
[0069]
【The invention's effect】
As described above in detail, according to the present invention, it was possible to obtain an external preparation for skin that has excellent stability and safety, and has synergistically improved effects of preventing and improving rough skin and aging of the skin.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002140844A JP3886116B2 (en) | 2002-05-16 | 2002-05-16 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002140844A JP3886116B2 (en) | 2002-05-16 | 2002-05-16 | Topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003335656A JP2003335656A (en) | 2003-11-25 |
| JP3886116B2 true JP3886116B2 (en) | 2007-02-28 |
Family
ID=29701592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002140844A Expired - Lifetime JP3886116B2 (en) | 2002-05-16 | 2002-05-16 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3886116B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006290749A (en) * | 2005-04-06 | 2006-10-26 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor |
| FR2912310B1 (en) * | 2007-02-13 | 2009-08-07 | Kasan Sarl | NOVEL COSMETIC AND / OR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS. |
| JP5171097B2 (en) * | 2007-04-17 | 2013-03-27 | 花王株式会社 | Heparin-binding epidermal growth factor-like growth factor gene expression promoter containing plant extract |
| CA2699813A1 (en) * | 2007-09-11 | 2009-03-19 | Joslin Diabetes Center, Inc. | Phase ii detoxification and antioxidant activity |
| KR101098581B1 (en) | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Composition for Improving Inflammatory Disorder Using ABH Antigen |
| JP6234533B1 (en) * | 2016-10-27 | 2017-11-22 | 株式会社ファンケル | Cleansing oil |
-
2002
- 2002-05-16 JP JP2002140844A patent/JP3886116B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003335656A (en) | 2003-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4685374B2 (en) | Topical skin preparation | |
| JP3583108B2 (en) | External preparation for skin | |
| JP2000143479A (en) | Whitening cosmetics | |
| JP3886116B2 (en) | Topical skin preparation | |
| JP3667291B2 (en) | Topical skin preparation | |
| JP3667027B2 (en) | Topical skin preparation | |
| BR102014025813A2 (en) | compositions comprising paulownia tomentosa wood extracts and uses thereof | |
| JP2003261417A (en) | Skin care preparation | |
| JP3719951B2 (en) | Skin preparation | |
| KR20090126992A (en) | Camellia gourd (camellia seed shell powder) and its use | |
| JP2003342181A (en) | Skin external preparation | |
| JP3597520B2 (en) | External preparation for skin | |
| JP3742281B2 (en) | Topical skin preparation | |
| JP3449967B2 (en) | External preparation for skin | |
| JP4045160B2 (en) | Skin preparation | |
| JP2004002218A (en) | External preparation for skin | |
| JP2003137798A (en) | Skin care preparation | |
| JP4077382B2 (en) | Skin preparation | |
| JP2003335651A (en) | Skin care preparation for external use | |
| JP2005298503A (en) | Moisture-retention cosmetic composition containing pulverized polygonatum offcinale | |
| JP3491755B1 (en) | External preparation for skin | |
| JP2003292451A (en) | Preparation for external use for skin | |
| KR20150050980A (en) | Cosmetic composition and external composition comprising Withania somnifera for anti-inflammatory | |
| JP2003335623A (en) | Skin care preparation for external use | |
| JP2003306440A (en) | Skin care preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050516 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060626 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20060626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061120 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3886116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091201 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121201 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121201 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131201 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |